Hemosol B0 (Calcium, Lactic Acid, Magnesium, Sodium, Chloride Ion, Hydrogen Carbonate)

HemoSol B0 is employed in clinical settings where haemodialysis is required to correct electrolyte and acid‑base disturbances. It is indicated for patients with renal failure undergoing dialysis, as well as for acute management of metabolic acidosis and electrolyte imbalances.

• Replacement of sodium, calcium, magnesium, chloride, and bicarbonate during haemodialysis.
• Correction of metabolic acidosis in end‑stage renal disease.
• Support of electrolyte balance in patients with acute kidney injury.
• Use as a dialysate component in continuous renal replacement therapy (CRRT).
• Adjunct therapy for patients receiving high‑flux haemodialysis where additional buffering is needed.

Side‑effect profiles for HemoSol B0 reflect its electrolyte composition and are generally related to infusion reactions or electrolyte shifts.

Common

• Mild transient hypotension during rapid infusion.
• Localized irritation at the catheter site.
• Slight increase in serum calcium or magnesium levels that resolves without intervention.
• Nausea or vomiting associated with rapid administration.
• Headache or dizziness related to electrolyte changes.

Serious

• Severe hypercalcemia leading to cardiac arrhythmia.
• Acute metabolic alkalosis requiring medical management.
• Anaphylactic reaction to solution components.
• Life‑threatening hypermagnesemia with neuromuscular depression.
• Pulmonary edema from fluid overload in susceptible patients.

When using HemoSol B0, clinicians should observe specific precautions to minimize risks associated with electrolyte and volume administration.

• Verify patient’s baseline serum electrolytes and acid‑base status before infusion.
• Adjust infusion rate in patients prone to hypotension or fluid overload.
• Avoid use in individuals with known hypersensitivity to any component of the solution.
• Monitor cardiac rhythm continuously in patients with pre‑existing arrhythmias.
• Use caution in pregnant or breastfeeding patients; safety data are limited.
• Ensure compatibility with other intravenous solutions to prevent precipitation.

HemoSol B0 may interact with other medications or solutions administered intravenously; awareness of potential interactions helps maintain patient safety.

Avoid

• Concurrent infusion of calcium‑containing drugs (e.g., calcium gluconate) that could cause hypercalcemia.
• Simultaneous administration of sodium bicarbonate solutions, which may lead to excessive alkalosis.

Use with caution

• Loop diuretics, which can amplify electrolyte shifts during dialysis.
• Anticoagulants used in haemodialysis circuits, requiring monitoring of clotting parameters.
• Blood pressure‑lowering agents, as rapid volume shifts may enhance hypotensive effects.